Decision Resources, Inc., announces the publication of Genomics Dealmaking in 2000 and Future Outlook: Bioinformatics, Gene Expression Monitoring, Microarrays, Proteomics, and Functional Genomics, a new DR Report that tracks industry trends in genomics deal-making. This report analyzes the implications of genomics-related dealmaking activity for companies competing in this arena and identifies the business opportunities generated by deals involving genomics technologies and related tools and services.

(Photo: )

Dealmaking activity in 2000 indicates that the focus of genomics deals is moving downstream from sequencing to gene expression monitoring, functional genomics, target validation, and proteomics. Bioinformatics was the most active area for genomics dealmaking in 2000, with deals in this sector increasingly focused on applications such as data mining and proteomics. The most critical sector of genomics research today, bioinformatics is an area in which some of the most rapid and significant advances are taking place. As the bioinformatics field matures, we project increased demand for integrated tools to analyze and manage data from various areas-for example, differential gene expression analysis using microarrays as well as the study and mapping of protein networks.

We conclude that using these downstream genomics technologies to link novel protein targets to critical disease-related functions and to refine drug leads already in development will be particularly important in the next two to three years. Developing drugs for totally novel targets will require additional technological innovation. Thus, in the shorter term, pharmaceutical companies that validate and patent new targets for drug development and discover clinical candidates that modulate them to fill product pipelines for the next decade will be in the best competitive positions.

Genomics Dealmaking in 2000 and Future Outlook is a DR Report published by Decision Resources, Inc. This report is available for $1,800.00.

Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

   Contact Fran Cameron, 781.296.2568 (tel), 781.296.2525 (fax), or    In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347    (fax), or    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel),    +81.3.5401.2617 (fax), or 



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, Inc., +1-781-296-2521,

A Decision Resources Primary Care Physician Survey Finds 20-25% Will Initially Remain Loyal to Branded Prozac

View Now